Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis
المؤلفون المشاركون
Abdulhamid, Ahmed
Trudeau, Sheri
Kaur, Nirmal
Parekh, Ravish
المصدر
Case Reports in Gastrointestinal Medicine
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-5، 5ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-05-15
دولة النشر
مصر
عدد الصفحات
5
التخصصات الرئيسية
الملخص EN
Background.
Outcome data regarding the use of tumor necrosis factor alpha inhibitors (anti-TNFα) in patients with inflammatory bowel disease (IBD) after liver transplant (LT) for primary sclerosing cholangitis (PSC) are scant.
Methods.
We performed a retrospective chart review to investigate outcomes among a series of post-liver-transplant PSC/IBD patients receiving anti-TNFα therapy at Henry Ford Health System ((HFHS), Detroit, MI).
Results.
A total of five patients were treated with anti-TNFα agents for IBD after LT for PSC from 1993 through 2015.
Two patients were treated with adalimumab, and three were treated with infliximab.
Three patients were hospitalized with severe posttransplant infections.
Two patients developed posttransplant lymphoproliferative disease (PTLD); one of these patients died due to complications of PTLD.
Conclusion.
Anti-TNFα treatment following LT worsened the disease course in our patients with concurrent PSC/IBD and led to serious complications and surgical intervention.
Larger studies are needed to evaluate the side effects and outcomes of the use of such agents in this patient population.
Until then, clinicians should have a high threshold to use anti-TNFα therapy in this setting.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Parekh, Ravish& Abdulhamid, Ahmed& Trudeau, Sheri& Kaur, Nirmal. 2018. Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis. Case Reports in Gastrointestinal Medicine،Vol. 2018, no. 2018, pp.1-5.
https://search.emarefa.net/detail/BIM-1143377
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Parekh, Ravish…[et al.]. Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis. Case Reports in Gastrointestinal Medicine No. 2018 (2018), pp.1-5.
https://search.emarefa.net/detail/BIM-1143377
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Parekh, Ravish& Abdulhamid, Ahmed& Trudeau, Sheri& Kaur, Nirmal. Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis. Case Reports in Gastrointestinal Medicine. 2018. Vol. 2018, no. 2018, pp.1-5.
https://search.emarefa.net/detail/BIM-1143377
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1143377
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر